MBRX
Moleculin Biotech, Inc.
There isn't enough reported data to score MBRX yet.
MBRX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
MBRX's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
MBRX PE Valuation
MBRX has no meaningful PE right now: it lost money over the past year.
MBRX Forward outlook
There aren't enough analyst estimates for MBRX to show an outlook.
MBRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$1,203.31 | +$4,680.63 |
| Q2 2025 | -$2,288.31 | +$3,595.63 |
| Q1 2025 | -$2,893.31 | +$3,640.63 |
| Q4 2024 | -$3,558.31 | +$4,065.63 |
| Q3 2024 | -$5,883.94 | +$916.14 |
| Q2 2024 | -$5,883.94 | +$1,741.14 |
| Q1 2024 | -$6,533.94 | +$1,391.14 |
| Q4 2023 | -$7,623.94 | +$1.14 |
MBRX is still losing money, but far less than before: $1,203.31 per share over the past year, against $16,200.00 at its worst in late 2019.
MBRX Quarterly Revenue
MBRX's revenue is shrinking: $0 last quarter.
MBRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$6.7M | -$1.1M |
| Q1 2026 | -$6.1M | -$1.5M |
| Q4 2025 | -$5.4M | -$283K |
| Q3 2025 | -$7.2M | -$1.1M |
| Q1 2025 | -$4.6M | +$2.2M |
| Q4 2024 | -$5.1M | +$405K |
| Q3 2024 | -$6.1M | +$1.5M |
| Q1 2024 | -$6.7M | -$700K |
MBRX has burned cash in almost every quarter: −$25M over the past year, against −$21M the year before.
MBRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +38% | +77.8K shares |
| 1 year | +1420% | +265K shares |
| 3 years | +7310% | +280K shares |
| 5 years | +9667% | +281K shares |
| Available history | +28022% | +283K shares |
MBRX has 284,036 diluted shares, up 1420% from a year ago.
MBRX Net Leverage
MBRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MBRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.7 | Neutral |
| Stochastic | 25.0 | Neutral |
MBRX's weekly RSI is 32 (neutral) and its Stochastic is 25 (neutral).
MBRX PE vs Healthcare Sector
MBRX has no meaningful PE right now: it lost money over the past year.
MBRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.42 | 4.3% below |
| 20 week MA | $17.4 | 54% below |
| 50 week MA | $45.4 | 82% below |
| 100 week MA | $237.5 | 97% below |
| 200 week MA | $2,059.1 | 100% below |
MBRX is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
MBRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $43,950.2 | $39,155.0 | -11% |
| 2021 | $39,155.0 | $15,225.0 | -61% |
| 2022 | $15,225.0 | $9,075.0 | -40% |
| 2023 | $9,075.0 | $6,440.0 | -29% |
| 2024 | $6,440.0 | $825.0 | -87% |
| 2025 | $825.0 | $76.6 | -91% |
| 2026 YTD | $76.6 | $8.06 | -89% |
MBRX has finished every year since 2020 lower, and it's down 89% so far in 2026.